Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
WEBLearning to live with both sleep apnea and pulmonary fibrosis. Living with pulmonary fibrosis is already a daunting challenge, but when coupled with a sleep disorder like sleep apnea, the burden becomes even heavier. Sleep apnea, a condition in which breathing repeatedly stops and starts during sleep, can significantly impact both sleep quality ...
BMS-986278 declared breakthrough therapy for progressive PF
WEBOct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with idiopathic PF (IPF) and progressive PF. Patients were assigned randomly to receive either 30 or 60 mg of the therapy, or a placebo ...
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis and Treatment
WEBRecent Posts. $15K award goes to researcher for work into IPF disease risk factors September 20, 2024; Learning to live with both sleep apnea and pulmonary fibrosis September 17, 2024; Navigating emotional ups and downs on my IPF journey September 17, 2024; Phase 2b trial tests AP01, inhaled pirfenidone, in progressive PF September 13, 2024; A new twist in my journey: Familial idiopathic ...
Esbriet, Ofev Found to Benefit IPF Patients in Clinical Practice
WEBApr 6, 2021 · Two approved anti-fibrotics are proving to be safe and effective in treating idiopathic pulmonary fibrosis (IPF), a study with real-world data reports. The data showed Esbriet (pirfenidone) and Ofev (nintedanib) increased progression-free survival, slowed down lung function decline, and reduced mortality in IPF patients.
Advocating for the idiopathic pulmonary fibrosis community in 2024
WEBJan 2, 2024 · About the Author. Samuel Kirton Sam Kirton started his column in November 2021 and writes from his home at Lake Anna, Virginia, where he lives with his wife Susan. His diagnosis at age 59 with idiopathic pulmonary fibrosis in January 2017 began a journey of awareness and advocacy. Sam was listed for a lung transplant on March 19, 2021 and ...
Top 10 Pulmonary Fibrosis Stories of 2021
WEBJan 3, 2022 · breathing exercises, Collagen turnover, esopremazole, MDM4, N115, pterostilbene, renin-angiotensin system, Salvianolic acid B, Top 10, TXR-1002, TXR-1007, Tyvaso, vitamin D. Pulmonary Fibrosis News counts down its top 10 most-read stories of 2021, noting what made each relevant for the PF community.
IPF Patients Live Longer on Ofev Compared with Placebo, Analysis …
WEBApr 16, 2019 · The analysis included data collected from a total of 1,126 IPF patients (mean age of 66.9 years), who were treated twice daily with 150 mg of Ofev, and 565 patients treated with a placebo. Participants received the treatment for a mean period of 27.7 months, with some patients receiving the treatment for a maximum of 93.1 months.
12 Facts About Pulmonary Fibrosis Prognosis and Life Expectancy
WEBAug 16, 2019 · The average life expectancy of patients with pulmonary fibrosis is three to five years after diagnosis. However, early detection of the disease is key to slowing progression, and conditions such as chronic obstructive pulmonary disease (COPD) or pulmonary arterial hypertension (PAH) can impact disease prognosis.
Study: ENV-101 improves IPF lung function, reverses fibrosis
WEBby Andrea Lobo June 7, 2024. Endeavor BioMedicines ’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The results, which also showed the treatment had an acceptable tolerability profile, were presented in a late ...
Ofev Approved in US and Canada for Progressive Fibrosing ILD
WEBMay 26, 2020 · These approvals, by the U.S. Food and Drug Administration (FDA) and Health Canada, come on the heels of findings from the INBUILD Phase 3 trial (NCT02999178), in which Ofev slowed the rate of lung function decline by 57% across a range of patients compared with placebo.. Ofev is the first medication approved in both countries for ILD patients whose chronic fibrosis continues to worsen over time.
Skip to content